TGTX — TG THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying TGTX?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their TGTX position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +1 tracked investor added or increased positions last quarter (Ray Dalio)
- +5 tracked investors reported holding TGTX at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About TG THERAPEUTICS INC (TGTX)
TG THERAPEUTICS INC (TGTX) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $81M. Across recent filings, tracked investors recorded 3 new positions, 2 increased, 1 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in TGTX
How many top investors track TGTX
A small number of top investors own this.
TGTX Ownership Composition
How TG THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant75.8%
- Macro24.2%
Tracked investors currently reporting TGTX
1 tracked investor has since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares1.2MValue$68.2M% Portfolio0.01%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares281.6KValue$15.5M% Portfolio0.01%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares367.2KValue$20.2M% Portfolio0.02%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares429.9KValue$23.6M% Portfolio0.10%
- Paul Tudor JonesJun 30, 2026Tudor Investment CorpShares173.1KValue$9.5M% Portfolio0.01%
Previously held TGTX
These investors reported TGTX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Stanley Druckenmiller | Duquesne Family Office | 280K | $4.3M | Mar 31, 2024 |
Recent activity
- New$12.4MNov 13, 2025
- Increased$14M(37.32%)Feb 13, 2026
- Reduced$10.3M(-33.72%)May 15, 2026
- Increased$23.6M(38.05%)Aug 14, 2026
- $1.5MAug 14, 2024
- Sold$0(-100.00%)Nov 14, 2024
- $4.3MMay 15, 2024
- $0(-100.00%)Aug 14, 2024
Frequently asked questions
- How many institutional investors hold TGTX?
- 5 tracked institutional investors disclosed a position in TGTX (TG THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of TGTX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in TGTX, valued at $81M.
- Did institutional ownership of TGTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 2 increased, 1 reduced, and 2 fully exited TGTX.
- Where does this TGTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.